Now: Neoadjuvant Olaparib window trial in patients with newly diagnosed BRCA mutant ovarian cancer (LBA 1)
Shannon N. Westin, Victoria Michael, Bryan Fellman, Larissa A. Meyer, Taylor Taylor, Tina Alvarado, Michaela Onstad Grinsfelder, Nicole D. Fleming, Aaron Shafer, Lauren Cobb, Michael W. Bevers, Anil K. Sood, Gordon B. Mills, Robert L. Coleman
Topics & Concepts
MedicineOlaparibBRCA mutationOncologyGynecologyOvarian cancerInternal medicineCancerPoly ADP ribose polymeraseGeneticsGenePolymeraseBiologyPARP inhibition in cancer therapyBRCA gene mutations in cancerOvarian cancer diagnosis and treatment